President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish territory, "for national security purposes." But Greenland Prime Minister ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec. 18 ...

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

Jakob Grauslund, D.M.Sci., PhD, MD, from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes.